[
  {
    "ts": null,
    "headline": "Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a prominent contender at the Cannes Lions International Festival of Creativity and secured 4 nominations on the Pharma shortlist for its campaigns related to Friedreich’s ataxia. This marks a significant presence for Biogen, […]",
    "url": "https://finnhub.io/api/news?id=8ce3d1fe66b61efebbbe8331394b083fa223a2085fb3356e3cdd574143eb28d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750884388,
      "headline": "Biogen’s Friedreich’s Ataxia Campaigns Earn 4 Cannes Lions Pharma Nominations",
      "id": 135532457,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the best S&P 500 stocks with huge upside potential. As of June 16, Biogen emerged as a prominent contender at the Cannes Lions International Festival of Creativity and secured 4 nominations on the Pharma shortlist for its campaigns related to Friedreich’s ataxia. This marks a significant presence for Biogen, […]",
      "url": "https://finnhub.io/api/news?id=8ce3d1fe66b61efebbbe8331394b083fa223a2085fb3356e3cdd574143eb28d1"
    }
  },
  {
    "ts": null,
    "headline": "Can Biogen Save Even More Kids With This New Drug?",
    "summary": "Can Biogen Save Even More Kids With This New Drug?",
    "url": "https://finnhub.io/api/news?id=3ab045e092b45b0a4b548c147855fbcd14317e2a66dae30a08b22078ec71f156",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750868345,
      "headline": "Can Biogen Save Even More Kids With This New Drug?",
      "id": 135989050,
      "image": "",
      "related": "BIIB",
      "source": "DowJones",
      "summary": "Can Biogen Save Even More Kids With This New Drug?",
      "url": "https://finnhub.io/api/news?id=3ab045e092b45b0a4b548c147855fbcd14317e2a66dae30a08b22078ec71f156"
    }
  },
  {
    "ts": null,
    "headline": "Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics",
    "summary": "The oligonucleotide synthesis market is forecasted to grow from USD 10.5 billion in 2025 to USD 24.7 billion by 2030 (CAGR of 18.6%). Key drivers include increasing demand for synthesized oligonucleotides for research and diagnostics, along with advancements in synthesis technology. By 2024, the oligonucleotide-based drugs segment is expected to dominate, driven by rising acceptance for treating rare diseases. North America leads the market due to established healthcare infrastructure and strong",
    "url": "https://finnhub.io/api/news?id=5933734a69830cc0d0d61813206e32f1c564b53a9e30255180dc0f7c77c7dafd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750862820,
      "headline": "Oligonucleotide Synthesis Market Research and Global Forecast Report 2025-2030: Rising Emphasis on Advancing Drug Delivery and Scalable Synthesis Technologies for Oligonucleotide-Based Therapeutics",
      "id": 135527220,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The oligonucleotide synthesis market is forecasted to grow from USD 10.5 billion in 2025 to USD 24.7 billion by 2030 (CAGR of 18.6%). Key drivers include increasing demand for synthesized oligonucleotides for research and diagnostics, along with advancements in synthesis technology. By 2024, the oligonucleotide-based drugs segment is expected to dominate, driven by rising acceptance for treating rare diseases. North America leads the market due to established healthcare infrastructure and strong",
      "url": "https://finnhub.io/api/news?id=5933734a69830cc0d0d61813206e32f1c564b53a9e30255180dc0f7c77c7dafd"
    }
  },
  {
    "ts": null,
    "headline": "Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results",
    "summary": "CARLSBAD, Calif., June 25, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA® (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and e",
    "url": "https://finnhub.io/api/news?id=d8112563459e015b2d757bf76ca532f1ea8b33aa7276e63e0d5354366c7fcae1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750851060,
      "headline": "Ionis announces Biogen to advance salanersen into SMA registrational studies based on positive interim Phase 1 results",
      "id": 135525426,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "CARLSBAD, Calif., June 25, 2025--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared positive topline results from the Phase 1 study of salanersen (ION306/BIIB115), an investigational antisense oligonucleotide (ASO) being developed for the potential treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA® (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and e",
      "url": "https://finnhub.io/api/news?id=d8112563459e015b2d757bf76ca532f1ea8b33aa7276e63e0d5354366c7fcae1"
    }
  },
  {
    "ts": null,
    "headline": "Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results",
    "summary": "Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to re",
    "url": "https://finnhub.io/api/news?id=434516bd824c3d1076c26cb9d25c6f392bd42be9a1308427eb71bf5171300774",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750851000,
      "headline": "Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results",
      "id": 135525427,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA)Interim Phase 1 data show children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersenBased on these encouraging Phase 1 data, Biogen is engaging with regulators to advance salanersen to re",
      "url": "https://finnhub.io/api/news?id=434516bd824c3d1076c26cb9d25c6f392bd42be9a1308427eb71bf5171300774"
    }
  },
  {
    "ts": null,
    "headline": "Biogen to Advance SMA Treatment Into Registrational Studies",
    "summary": "Biogen to Advance SMA Treatment Into Registrational Studies",
    "url": "https://finnhub.io/api/news?id=ef90bcf2c6477c2e9aebc81fc96aa58764f7a1305ae955963929efc03e676210",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750838220,
      "headline": "Biogen to Advance SMA Treatment Into Registrational Studies",
      "id": 135989074,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen to Advance SMA Treatment Into Registrational Studies",
      "url": "https://finnhub.io/api/news?id=ef90bcf2c6477c2e9aebc81fc96aa58764f7a1305ae955963929efc03e676210"
    }
  }
]